YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
Status:
Terminated
Trial end date:
2004-02-01
Target enrollment:
0
Participant gender:
Male
Summary
The purpose of this study is to determine the optimal dosage of YM598 for slowing down
disease progression in patients with rising PSA after initial therapy for localized prostate
cancer.